P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. Click here to read the entire release. […]
P2D Bioscience has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007’s efficacy at inhibiting dopamine transport in multiple brain […]